Efficacy Data Support Nivolumab/Ipilimumab as First-Line HCC Treatment
Survival and safety data from the phase 3 CheckMate 9DW trial showed that nivolumab plus ipilimumab was superior to lenvatinib or sorafenib in advanced HCC.
Related Articles
IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer
Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.
ONCOLOGY Vol 39, Issue 4
CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
Pulsed Electric Field Ablation May Show Feasibility, Safety in Early NSCLC
Data from the INCITE-ES study show 100% technical success with pulsed electric field energy delivery before surgical resection.
AI Transforms HER2-Low, HER2-Ultralow Breast Cancer Diagnostics for Pathologists
AI-assisted training dramatically reduced HER2-null overscoring and improved sensitivity in HER2-low and HER2-ultralow breast cancer cases.
Inavolisib Combo Significantly Extends Survival in PIK3CA+ Breast Cancer
Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.
GLP-1 Use Not Linked to Increased Obesity-Related Cancer Rates
There was a 7% lower incidence of obesity-related cancer with GLP-1 receptor agonist use.
Frontline Lurbinectedin Plus Atezolizumab Enhances Survival in ES-SCLC
The phase 3 IMforte trial evaluating lurbinectedin plus atezolizumab is the first to show PFS and OS improvement with first-line maintenance for ES-SCLC.
Telisotuzumab Vedotin Earns FDA Accelerated Approval in c-MET+ NSCLC
Data from the phase 2 LUMINOSITY study support the FDA approval of telisotuzumab vedotin in this non–small cell lung cancer population.
Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
Experts share clinical pearls on synthesizing risk assessment and response patterns in the management of advanced renal cell carcinoma.
Obe-Cel Receives Positive CHMP Opinion for R/R B-Cell ALL
The positive CHMP opinion is based on results from the phase 1b/2 FELIX trial evaluating obe-cel in relapsed/refractory B-cell ALL.